The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
Key Clinical Message There is no effective treatment that reduces both the severity and duration of a common cold episode. SJP − 002 (naproxen and fexofenadine) reduced symptom severity by two‐third, and the duration of the common cold episode approximately by half. Abstract The common cold is one o...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-07-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.7682 |
_version_ | 1797772051451215872 |
---|---|
author | Emina Išerić Thomas A. Dahl Andrew Scholey Jacqueline M. Iversen Joris C. Verster |
author_facet | Emina Išerić Thomas A. Dahl Andrew Scholey Jacqueline M. Iversen Joris C. Verster |
author_sort | Emina Išerić |
collection | DOAJ |
description | Key Clinical Message There is no effective treatment that reduces both the severity and duration of a common cold episode. SJP − 002 (naproxen and fexofenadine) reduced symptom severity by two‐third, and the duration of the common cold episode approximately by half. Abstract The common cold is one of the most frequently experienced immune‐related complaints. At present, available treatments have limited efficacy in inhibiting symptoms associated with upper respiratory tract infection, nor do they significantly shorten the duration of common cold episodes. Four case reports are presented of individuals with a common cold. Three of them self‐administered the combination of naproxen and fexofenadine (SJP − 002). Results of one individual were compared to her spouse, who did not take SJP − 002 to treat common cold, while two other individuals took SJP − 002 and compared symptom severity with another common cold episode they experienced previously without taking SJP − 002. SJP − 002 reduced the severity of symptoms associated with upper respiratory tract infection by two‐third and reduced the duration of the common cold episode approximately by half. In conclusion, SJP − 002 reduced the severity and duration of common cold episodes. These findings warrant further investigation of SJP − 002 in double‐blind, placebo‐controlled clinical trials. |
first_indexed | 2024-03-12T21:45:24Z |
format | Article |
id | doaj.art-8f080281f022427fb73784f700d7ee6f |
institution | Directory Open Access Journal |
issn | 2050-0904 |
language | English |
last_indexed | 2024-03-12T21:45:24Z |
publishDate | 2023-07-01 |
publisher | Wiley |
record_format | Article |
series | Clinical Case Reports |
spelling | doaj.art-8f080281f022427fb73784f700d7ee6f2023-07-26T12:00:46ZengWileyClinical Case Reports2050-09042023-07-01117n/an/a10.1002/ccr3.7682The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common coldEmina Išerić0Thomas A. Dahl1Andrew Scholey2Jacqueline M. Iversen3Joris C. Verster4Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht University Utrecht The NetherlandsSen‐Jam Pharmaceutical Huntington New York USANutrition Dietetics and Food, School of Clinical Sciences Monash University Melbourne Victoria AustraliaSen‐Jam Pharmaceutical Huntington New York USADivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS) Utrecht University Utrecht The NetherlandsKey Clinical Message There is no effective treatment that reduces both the severity and duration of a common cold episode. SJP − 002 (naproxen and fexofenadine) reduced symptom severity by two‐third, and the duration of the common cold episode approximately by half. Abstract The common cold is one of the most frequently experienced immune‐related complaints. At present, available treatments have limited efficacy in inhibiting symptoms associated with upper respiratory tract infection, nor do they significantly shorten the duration of common cold episodes. Four case reports are presented of individuals with a common cold. Three of them self‐administered the combination of naproxen and fexofenadine (SJP − 002). Results of one individual were compared to her spouse, who did not take SJP − 002 to treat common cold, while two other individuals took SJP − 002 and compared symptom severity with another common cold episode they experienced previously without taking SJP − 002. SJP − 002 reduced the severity of symptoms associated with upper respiratory tract infection by two‐third and reduced the duration of the common cold episode approximately by half. In conclusion, SJP − 002 reduced the severity and duration of common cold episodes. These findings warrant further investigation of SJP − 002 in double‐blind, placebo‐controlled clinical trials.https://doi.org/10.1002/ccr3.7682common coldfexofenadinenaproxenrhinovirusSJP − 002treatment |
spellingShingle | Emina Išerić Thomas A. Dahl Andrew Scholey Jacqueline M. Iversen Joris C. Verster The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold Clinical Case Reports common cold fexofenadine naproxen rhinovirus SJP − 002 treatment |
title | The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold |
title_full | The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold |
title_fullStr | The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold |
title_full_unstemmed | The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold |
title_short | The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold |
title_sort | efficacy of a combination of naproxen and fexofenadine sjp 002 to inhibit the symptoms that are associated with viral upper respiratory tract infection four case reports of individuals with common cold |
topic | common cold fexofenadine naproxen rhinovirus SJP − 002 treatment |
url | https://doi.org/10.1002/ccr3.7682 |
work_keys_str_mv | AT eminaiseric theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT thomasadahl theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT andrewscholey theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT jacquelinemiversen theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT joriscverster theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT eminaiseric efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT thomasadahl efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT andrewscholey efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT jacquelinemiversen efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold AT joriscverster efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold |